News

Medical Dialogues14h

Novartis ianalumab Phase III trial meets primary endpoint in immune thrombocytopenia

Basel: Novartis has announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag ...